Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 12, 2022 at 06:19 am EDT
Share
Kiora Pharmaceuticals, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 2.4 million compared to USD 2.54 million a year ago. Basic loss per share from continuing operations was USD 7.2 compared to USD 13.6 a year ago. Diluted loss per share from continuing operations was USD 7.2 compared to USD 13.6 a year ago.
For the six months, net loss was USD 5.97 million compared to USD 4.55 million a year ago. Basic loss per share from continuing operations was USD 18.4 compared to USD 24.4 a year ago. Diluted loss per share from continuing operations was USD 18.4 compared to USD 24.4 a year ago.
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of orphan retinal diseases. Its pipeline consists of three product candidates, including KIO-301, KIO-104, KIO-101 and KIO-201. Its lead product, KIO-301, is a vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). KIO-104 is a next generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH), which is being develop for the treatment of Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases, including rheumatoid arthritis, and as such is termed the Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+).
KIORA PHARMACEUTICALS, INC. 
